10-year performance of four models of breast cancer risk: a validation study.
暂无分享,去创建一个
Gord Glendon | Mary Beth Terry | John L Hopper | Irene L Andrulis | Julia A Knight | Gillian S Dite | Roger L Milne | Graham G Giles | Alice S Whittemore | Melissa C Southey | Wendy K Chung | A. Whittemore | W. Chung | G. Giles | J. Hopper | E. John | M. Southey | S. Buys | R. Milne | I. Andrulis | J. Knight | G. Glendon | G. Dite | M. Friedlander | M. Daly | D. Goldgar | M. Terry | R. MacInnis | Y. Liao | R. Buchsbaum | K. Phillips | S. McLachlan | N. Zeinomar | Kelly-Anne Phillips | Robert J MacInnis | Mary B Daly | Esther M John | Saundra S Buys | David Goldgar | P. Weideman | S. Nesci | Nicole M Leoce | Richard Buchsbaum | Yuyan Liao | Prue C Weideman | Stephanie Nesci | Michael L Friedlander | Sue-Anne McLachlan | Nicole Leoce | Nur Zeinomar | Nicole M. Leoce | Stephanie Nesci
[1] Sabine Van Huffel,et al. A spline-based tool to assess and visualize the calibration of multiclass risk predictions , 2015, J. Biomed. Informatics.
[2] D. Easton,et al. Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries , 2017, Familial Cancer.
[3] Danielle Braun,et al. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications , 2017, Breast Cancer Research and Treatment.
[4] Alice S Whittemore,et al. Evaluating health risk models , 2009, Statistics in medicine.
[5] J. Hopper,et al. Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer , 2017, British Journal of Cancer.
[6] A. Whittemore,et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.
[7] John L Hopper,et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.
[8] J. Emery,et al. Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study , 2020, PloS one.
[9] A. Whittemore,et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.
[10] J. Long,et al. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women , 2020, Breast Cancer Research and Treatment.
[11] Norman Boyd,et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.
[12] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[13] Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC) , 2018, Breast Cancer Research.
[14] D Spiegelman,et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.
[15] Roger Newson,et al. Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .
[16] H A Risch,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.
[17] Martin Eklund,et al. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial , 2017, Journal of the National Cancer Institute.
[18] G. Colditz,et al. Breast cancer risk accumulation starts early: prevention must also , 2014, Breast Cancer Research and Treatment.
[19] A. Whittemore,et al. Practical Problems With Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk , 2015, Journal of the National Cancer Institute.
[20] Jack Cuzick,et al. Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density , 2018, JAMA oncology.
[21] J. Hopper,et al. Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic System. , 2017, Radiology.
[22] Stephen W Duffy,et al. A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.
[23] S. Astley,et al. Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction , 2018, JAMA oncology.
[24] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[25] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[26] Ahmedin Jemal,et al. Global Cancer in Women: Burden and Trends , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[27] Yvonne Vergouwe,et al. A calibration hierarchy for risk models was defined: from utopia to empirical data. , 2016, Journal of clinical epidemiology.
[28] J. Emery,et al. iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management , 2016, Breast Cancer Research and Treatment.
[29] E. Friedman,et al. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. , 2013, Genetics research.
[30] M. Pearlman,et al. Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference , 2020, Obstetrics and gynecology.
[31] G. Giles,et al. Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[32] G. Giles,et al. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre , 2013, British Journal of Cancer.
[33] J. Hopper,et al. Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort , 2004, Familial Cancer.
[34] Kaitlin Farrell,et al. Screening for Breast Cancer: What You Need to Know. , 2020, Missouri medicine.
[35] Susan M. Astley,et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort , 2015, Breast Cancer Research.
[36] D. Kennedy,et al. Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR. , 2008, Carcinogenesis.
[37] Konstantin Strauch,et al. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance , 2012, Breast Cancer Research.
[38] Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer , 2011, Familial Cancer.
[39] Wei Yang,et al. Development of screening tools to predict the risk of recurrence and related complications following anal fistula surgery: protocol for a prospective cohort study , 2020, BMJ Open.
[40] A Howell,et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.